Related Experiment Videos
Adverse cardiac effects associated with clozapine
David B Merrill1, G William Dec, Donald C Goff
1New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York, NY 10032, USA. david_merrill@post.harvard.edu
Journal of Clinical Psychopharmacology
|January 12, 2005
Summary
Clozapine use carries a low risk of serious cardiac events like myocarditis, but its benefits in reducing suicide risk often outweigh these dangers. Guidelines are provided for cardiac monitoring during clozapine treatment.
Area of Science:
- Pharmacology
- Cardiology
- Psychiatry
Background:
- Atypical antipsychotics, including clozapine, are used for treatment-resistant schizophrenia.
- Serious adverse cardiac events are a concern with clozapine therapy.
- Cardiac monitoring protocols for clozapine initiation are essential.
Purpose of the Study:
- To review literature on clozapine-associated cardiac adverse events.
- To establish recommendations for cardiac assessment before and during clozapine treatment.
Main Methods:
- Systematic literature search of PubMed and MEDLINE (1970-2004).
- Keywords included "clozapine" combined with cardiac terms.
- Review of 30 identified case reports, trials, and reviews.
Main Results:
- Clozapine is linked to a low risk (0.015%-0.188%) of potentially fatal myocarditis or cardiomyopathy.
- Clozapine is not independently associated with QTc prolongation but may contribute in at-risk patients.
- The overall risk of cardiac events is considered low.
Conclusions:
- The low risk of cardiac adverse events is generally outweighed by clozapine's efficacy in suicide reduction.
- Recommendations for cardiac assessment and monitoring are provided for clozapine therapy.
- Proactive cardiac surveillance is crucial for patients on clozapine.